Today, Baird Capital portfolio company GreenLight Biosciences (GreenLight) announced it raised an oversubscribed $102 million, Series D round of funding from new and existing investors. GreenLight aims to rapidly expand the production of its RNA products for agricultural and life sciences applications, including expanding into new RNA-based therapies.

The investment comes on the heels of a $17 million special purpose round in May 2020 to build out its scalable mRNA production capability targeting the production of billions of doses of COVID-19 vaccine.